Aveanna Healthcare Holdings Inc. (AVAH)
| Market Cap | 2.76B +86.9% |
| Revenue (ttm) | 2.60B +19.5% |
| Net Income | 274.76M +1,380.8% |
| EPS | 1.23 +1,199.5% |
| Shares Out | 218.22M |
| PE Ratio | 10.28 |
| Forward PE | 15.12 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,047,346 |
| Open | 12.68 |
| Previous Close | 12.69 |
| Day's Range | 12.23 - 12.76 |
| 52-Week Range | 5.93 - 12.76 |
| Beta | 1.92 |
| Analysts | Buy |
| Price Target | 12.35 (-2.53%) |
| Earnings Date | Aug 13, 2026 |
About AVAH
Aveanna Healthcare Holdings Inc., a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities. The company operates through three segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The PDS segment offers private duty nursing (PDN) services, which include in... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for AVAH stock is "Buy." The 12-month stock price target is $12.35, which is a decrease of -2.53% from the latest price.
News
Aveanna reports Q2 EPS 18c, consensus 17c
Reports Q2 revenue $670.48M, consensus $639.63M. Jeff Shaner, Chief Executive Officer, commented, “Our second quarter results demonstrate the momentum across Aveanna (AVAH) and our ability to consiste...
Aveanna backs FY26 revenue view $2.63B-$2.65B, consensus $2.63B
Raises FY26 adjusted EBITDA view to greater than $365M from $338M-$342M. Matt Buckhalter, Chief Financial Officer, commented “Aveanna’s (AVAH) second quarter results continued our momentum with our te...
Aveanna price target raised to $14 from $10 at BMO Capital
BMO Capital raised the firm’s price target on Aveanna (AVAH) to $14 from $10 and keeps an Outperform rating on the shares. The company delivered another beat-and-raise with Q2 revenue…
Aveanna price target raised to $13 from $8 at UBS
UBS raised the firm’s price target on Aveanna (AVAH) to $13 from $8 and keeps a Neutral rating on the shares. The firm updated its model to reflect Aveanna’s updated…
Aveanna price target raised to $15 from $13 at Raymond James
Raymond James raised the firm’s price target on Aveanna (AVAH) to $15 from $13 and keeps a Strong Buy rating on the shares. Aveanna’s Q2 EBITDA beat and higher guidance…
Aveanna price target raised to $16 from $11.50 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Aveanna (AVAH) to $16 from $11.50 and keeps a Buy rating on the shares.
Aveanna Healthcare Holdings Earnings Call Transcript: Q2 2026
Q2 2026 saw 13.7% revenue growth and 8% adjusted EBITDA growth, driven by strong segment performance and operational efficiencies. Guidance for 2026 was raised, with higher long-term growth rates and continued focus on preferred payer strategies, M&A, and deleveraging.
Aveanna Healthcare Holdings Earnings release: Q2 2026
Aveanna Healthcare Holdings released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Aveanna Healthcare Holdings Quarterly report: Q2 2026
Aveanna Healthcare Holdings has published its Q2 2026 quarterly earnings report on August 13, 2026.
Aveanna Healthcare Holdings Slides: Investor presentation
Aveanna Healthcare Holdings has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
Aveanna Healthcare Holdings Announces Second Quarter Financial Results and Revised 2026 Guidance
Second Quarter Revenue was $670.5 million, a 13.7% increase over the prior year period Second Quarter Net income was $40.3 million compared to $27.0 million for the prior year period Adjusted EBITDA f...
Aveanna Announces Second Quarter 2026 Earnings Release Date and Conference Call
ATLANTA, July 23, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that the company will release its second quarter results before the market open o...
Aveanna price target raised to $11 from $9 at Truist
Truist raised the firm’s price target on Aveanna (AVAH) to $11 from $9 and keeps a Hold rating on the shares as part of a broader research note previewing Q2…
Aveanna price target raised to $9.50 from $9 at Barclays
Barclays raised the firm’s price target on Aveanna (AVAH) to $9.50 from $9 and keeps an Overweight rating on the shares. The firm adjusted targets among its U.S. healthcare facilities…
Aveanna upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital upgraded Aveanna (AVAH) to Outperform from Sector Perform with an unchanged price target of $10. The firm cites the company’s “solid execution” on preferred payor relationships for the…
Aveanna Healthcare Holdings Transcript: 46th Annual William Blair Growth Stock Conference
Fourteen consecutive quarters of outperformance and strategic acquisitions have driven strong revenue and EBITDA growth, with updated 2026 guidance reflecting recent M&A. Preferred payer and value-based strategies underpin stable, diversified growth, while disciplined financial management supports ongoing de-leveraging and expansion.
Aveanna raises FY26 revenue view to $2.63B-$2.65B from $2.56B-$2.58B
Consensus $2.6B. Raises FY26 adjusted EBITDA view to $338M-$342M from $328M-$332M. Aveanna (AVAH) announced that it completed its acquisition of Family First Holding. Aveanna acquired Family First Hom...
Aveanna Healthcare Holdings Completes Acquisition of Family First Homecare and Updates Full Year 2026 Guidance
ATLANTA, June 02, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient ...
Aveanna Healthcare Announces Successful Debt Repricing
ATLANTA, May 28, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (Nasdaq: AVAH), a leading, diversified home care platform focusing on providing care to medically complex, high-c...
Aveanna price target raised to $9 from $8 at Truist
Truist analyst David MacDonald raised the firm’s price target on Aveanna (AVAH) to $9 from $8 and keeps a Hold rating on the shares after its Q1 earnings beat. Cor…
Aveanna price target lowered to $9 from $9.50 at Barclays
Barclays lowered the firm’s price target on Aveanna (AVAH) to $9 from $9.50 and keeps an Overweight rating on the shares post the Q1 report. The firm upped the company’s’…
Aveanna price target raised to $10 from $9 at RBC Capital
RBC Capital analyst Ben Hendrix raised the firm’s price target on Aveanna (AVAH) to $10 from $9 and keeps a Sector Perform rating on the shares. The company delivered a…
Aveanna upgraded to Overweight at Stephens on ‘beat-and-raise’ momentum
As previously reported, Stephens analyst Scott Fidel upgraded Aveanna (AVAH) to Overweight from Equal Weight with a price target of $11, up from $10. Aveanna has delivered a “sustained cadence…
Aveanna upgraded to Overweight from Equal Weight at Stephens
Stephens upgraded Aveanna (AVAH) to Overweight from Equal Weight with an $11 price target
Aveanna Healthcare Holdings Earnings Call Transcript: Q1 2026
Q1 2026 saw 15.9% revenue growth and 25.2% adjusted EBITDA growth, driven by preferred payer strategies and operational efficiencies. Guidance for 2026 was raised, and the Family First Homecare acquisition is set to close in late Q2.